Avomeen Analytical Services has appointed Khanh Courtney as its Biological Chemistry Project Director. In this newly created position, Courtney will help grow Avomeen’s large-molecule and protein therapeutics business segment by partnering with biopharmaceutical clients who are navigating the large-molecule product development life cycle.

“We are excited to expand our large-molecule and protein therapeutics offerings through this new position,” said Mark Harvill, Avomeen Chief Executive Officer. “With Khanh’s scientific expertise in large molecules and her past biotech experience, we know she was the perfect choice to help us grow this business segment.”

Courtney began her career as a postdoctoral researcher first at Stanford University for two years and then at University of California – San Francisco. Since 2016, she worked as a quality control scientist at BioMarin Pharmaceutical. There, she provided technical guidance for biologics testing, troubleshooting and investigations within the quality control department. She also served as a leader for developing new methods and optimizing existing ones.

Throughout her career, Courtney has gained extensive expertise in protein biochemistry and molecular biology within many different settings. These include R&D and analytical method development, validation, implementation, method transfers, and test method optimization for current Good Manufacturing Practices settings per United States Pharmacopeia and International Council for Harmonisation guidelines. Her experience also equips her well to respond to inquiries from the U.S. Food and Drug Administration, European Medicines Agency, and Prescription Drug Marketing Act as well as author analytical sections in Biologics License and Marketing Authorization Applications, which will all be necessary in her new position.